Evidence map›Paper›PMID 42737921›Full record

ArticleBiology2026

Single-Molecule AFM-Based Force Spectroscopy Reveals VLA-4/VCAM-1 Interactions Underlying Chemokine-Independent B16 Melanoma Cell Arrest.

Robert H Eibl

Abstract read
In one paragraph

Article in Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Robert H EiblInstitute of Pathology, Technical University of Munich, Trogerstr. 18, 81675 Munich, Germany.ORCID 0000-0002-6687-5286

Funding

Center for NanoScienceInstitute of Applied Physics at Ludwig-Maximilians-Universität MünchenMax Planck Institute for Polymer ResearchStanford UniversityTechnical University of Munich
6 · The paper itself

Abstract

Integrin-mediated adhesion is essential for leukocyte trafficking and contributes to hematogenous tumor metastasis. We recently showed that metastatic B16 melanoma cells undergo VLA-4-dependent rolling and rapid arrest on endothelial cells under physiological shear flow without classical chemokine-induced integrin activation. However, the molecular basis of this chemokine-independent adhesion remained unresolved. Here, atomic force microscopy (AFM)-based single-molecule force spectroscopy was used to characterize VLA-4-mediated adhesion between living B16 melanoma cells and bEnd.3 endothelial cells at the level of individual receptor-ligand interactions. Rupture-force histograms revealed a dominant population centered at approximately 33 pN, consistent with single VLA-4/VCAM-1 bonds. VLA-4 blockade reduced adhesion frequency, whereas VCAM-1 blockade shifted the rupture-force distribution toward lower forces; both effects support molecular specificity. VLA-4-directed antibody and pharmacological inhibition further indicated that regulation primarily affects bond-formation probability rather than the strength of individual receptor-ligand interactions. Homotypic VLA-4-mediated adhesion between melanoma cells was also detected. These findings provide a functional link between single-molecule receptor interactions and the rolling-to-arrest transition of metastatic melanoma cells under physiological flow. Together with our recent flow-chamber studies, they support a model in which VLA-4/VCAM-1 bond formation contributes to vascular arrest without requiring classical integrin activation, providing molecular insight into an early step of metastatic dissemination.

Indexed as

atomic force microscopy (AFM)B16 melanomacell adhesioncell migrationintegrin inhibitormetastasissingle-molecule force spectroscopyVCAM-1VLA-4

Identifiers

PMID42737921
PMCPMC13564867

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.